Source comparison
Tesamorelin + Ipamorelin Blend Peptide: Clinical Research Comparison
Peak GH Output (ng/mL) 6.1 ± 1.8 5.7 ± 1.4 18.4 ± 3.2 The blend produces 3× higher peak GH through dual-pathway activation. The effect is multiplicative, not additive Cortisol Elevation Minimal (<5% increase) None (cortisol-neutral) Ipamorelin's selective ghre
This comparison does not assign a generated winner or score.
- Peak GH Output (ng/mL)
- 6.1 ± 1.8
- 5.7 ± 1.4
- 18.4 ± 3.2
- The blend produces 3× higher peak GH through dual-pathway activation. The effect is multiplicative, not additive
- Cortisol Elevation
- Minimal (<5% increase)
- None (cortisol-neutral)
- Ipamorelin's selective ghrelin receptor binding prevents the cortisol spikes seen with GHRP-6 and hexarelin
- Duration of GH Elevation
- 90–120 minutes
- 120–150 minutes
- 150–180 minutes
- The blend extends the GH pulse duration because tesamorelin maintains receptor occupancy while ipamorelin drives secretion
- Receptor Desensitization Risk
- Moderate (cAMP pathway fatigue after 8+ weeks daily dosing)
- Low (minimal tachyphylaxis at standard doses)
- Low (alternating pathway usage reduces individual receptor fatigue)
- The dual-mechanism approach preserves sensitivity better than single-pathway protocols over 12+ week studies
- The comparison table above reflects data compiled from Phase 2 pharmacokinetic trials and published endocrinology research. The blend's performance advantage becomes most apparent in extended protocols where single-peptide regimens begin to show diminished response after 6–8 weeks.